Asked by: Ben Spencer (Conservative - Runnymede and Weybridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure consistency of the supply of medication for (a) epilepsy and b) Parkinson's disease patients.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department is working hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including directing suppliers to expedite deliveries, some issues, including with some carbamazepine and oxcarbazepine presentations, have been resolved.
There was a supply issue with all strengths of lamotrigine tablets, used to manage epilepsy, due to manufacturing issues. The supply issue has recently resolved, and supply is expected to return to normal levels through early December 2024.
We are aware of an ongoing supply issue with all strengths of topiramate tablets, with the resupply date to be confirmed. Other manufacturers of topiramate tablets can meet the increased demand during this time.
The Department is aware of supply constraints with one supplier of amantadine 100 milligram capsules, used in the management of Parkinson’s disease, however stocks remain available from alternative suppliers to cover this demand.
The Department continues to work closely with industry, the National Health Service, and others to help ensure patients continue to have access to an alternative treatment until their usual product is back in stock.
Asked by: Sarah Green (Liberal Democrat - Chesham and Amersham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to promote awareness of early symptoms of Parkinson's disease amongst GPs.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
General practitioners (GPs) are responsible for ensuring their own clinical knowledge, including of Parkinson’s disease, remains up-to-date, and for identifying learning needs as part of their continuing professional development. This activity should include taking account of new research and developments in guidance, such as that produced by the National Institute for Health and Care Excellence, to ensure that they can continue to provide high quality care to all patients. All doctors registered in the United Kingdom are expected to meet the professional standards set out in the General Medical Council’s (GMC’s) Good Medical Practice. In 2012, the GMC introduced revalidation, which supports doctors in regularly reflecting on how they can develop or improve their practice, giving patients confidence that doctors are up to date with their practice, and promoting improved quality of care by driving improvements in clinical governance.
The training curricula for postgraduate trainee doctors, set by the Royal College of General Practitioners, has to meet the standards set by the GMC. Whilst curricula do not necessarily highlight specific conditions for doctors to be aware of, they do emphasise the skills and approaches that a doctor must develop to ensure accurate and timely diagnoses and treatment plans for their patients.
Asked by: Sarah Green (Liberal Democrat - Chesham and Amersham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding the Government provides for research into a cure for Parkinson's disease.
Answered by Andrew Gwynne
The Government’s responsibility for delivering Parkinson’s disease research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department of Science, Innovation and Technology, with research delivered via UK Research and Innovation. The Government spent a total of £79.06 million on research into Parkinson’s disease between the financial years 2019/20 and 2023/24.
As well as funding research itself, the NIHR invests significantly in research expertise and capacity, specialist facilities, support services, and collaborations to support and deliver research in England. Collectively, this forms the NIHR’s infrastructure. The NIHR’s infrastructure enables the country’s leading experts to develop and deliver high-quality translational, clinical, and applied research into Parkinson’s disease. For example, in the financial year 2022/23, the NIHR Clinical Research Network enabled 114 studies related to Parkinson’s disease.
Asked by: Sarah Green (Liberal Democrat - Chesham and Amersham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of consultants specialising in the treatment of Parkinson's disease required to meet current needs of patients.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We have launched a 10-Year Health Plan to reform the National Health Service. A central and core part of the plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.
No such estimate has been made. We are committed to training the staff we need, including neurologists and consultants specialising in treating Parkinson’s Disease, to ensure that patients are cared for by the right professional, when and where they need it.
As of August 2024, there are 1,917 full-time equivalent (FTE) doctors working in the specialty of neurology in NHS trusts and integrated care boards in England, which is 146, or 8.2%, more than a year ago, and 473, or 32.7%, more than five years ago. Of these, there are 975 FTE consultants, which is 47, or 5%, more than a year ago, and 179, or 22.5%, more than five years ago. In 2024, there are 367 doctors in the NHS in England in postgraduate specialty training for neurology. This is 44, or 13.6%, more than five years ago.
Asked by: Sarah Green (Liberal Democrat - Chesham and Amersham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to his strategy for NHS workforce planning, if he will make an assessment of the potential impact of shortages in the number of clinicians specialising in neurology on the adequacy of care for patients with (a) Parkinson's Disease and (b) other neurological conditions.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Currently, there are no specific plans to make an assessment of the potential impact of shortages in the number of clinicians specialising in neurology on the adequacy of care for patients with Parkinson's disease or other neurological conditions.
As of July 2024, there were over 1,800 full-time equivalent (FTE) doctors working in the specialty of neurology in National Health Service trusts and other organisations in England. This includes over 900 FTE consultant neurologists. In 2023, the fill rate for recruitment into the specialty of neurology in England was 94%.
The NHS workforce has been overworked for years, leading to staff becoming burnt out and demoralised. We must be honest about the challenges we are facing. The NHS is broken but not beaten and together we will turn it around.
We have launched a 10-Year Health Plan to reform the NHS. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention. A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.
There are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme (NTP).
The GIRFT National Specialty Report made recommendations designed to improve services nationally and to support the NHS to deliver care more equitably across the country. In addition, the NTP has developed a model of integrated care for neurology services to support integrated care boards to deliver the right service, at the right time for all neurology patients, including providing care closer to home.
Asked by: Martin Wrigley (Liberal Democrat - Newton Abbot)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to mitigate the impact of shortages of medicines for people with (a) epilepsy and (b) Parkinson's disease.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department is working hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including directing suppliers to expedite deliveries, some issues, including with some carbamazepine and oxcarbazepine presentations, have been resolved.
There is a supply issue with all strengths of lamotrigine tablets, used to manage epilepsy, due to manufacturing issues. A supply issue with one of the strengths of lamotrigine tablets has recently resolved, and the remaining strengths are expected to resolve from early December 2024. Other manufacturers of lamotrigine tablets can meet the increased demand during this time.
The Department is aware of supply constraints with one supplier of amantadine 100mg capsules used in the management of Parkinson’s Disease, however stocks remain available from alternative suppliers to cover this demand.
The Department continues to work closely with industry, the NHS and others to help ensure patients continue to have access to an alternative treatment until their usual product is back in stock.
Asked by: Sarah Green (Liberal Democrat - Chesham and Amersham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the number of specialist Parkinson's Nurses required to meet the current needs of patients.
Answered by Andrew Gwynne
The Department does not hold data specifically on the number of people waiting for treatment for Parkinson’s disease in England. The Department does hold data on waiting times for neurology, but not broken down by specific conditions. The latest data for referral to treatment waiting times in England, from September 2024, shows there were over 234,000 patients waiting for a neurology appointment, and that 54% of patients were seen by a neurologist within 18 weeks.
There are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme (NTP).
The GIRFT National Specialty Report made recommendations designed to improve services nationally, and to support the National Health Service to deliver care more equitably across the country. The report highlighted differences in how services are delivered, and provided the opportunity to share successful initiatives between trusts to improve patient services nationally. In addition, the NTP has developed a model of integrated care for neurology services to support integrated care boards to deliver the right service, at the right time for all neurology patients, including providing care closer to home.
Once diagnosed, and with a management strategy in place, the majority of people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 neurology centres across England. Within specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support according to their needs.
No specific assessment has been made of the number of specialist Parkinson’s nurses required to meet the current need of patients in England. While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the numbers working in the wider speciality of neurology. As of July 2024, there were over 1,800 full-time equivalent (FTE) doctors working in the specialty of neurology in NHS trusts and other organisations in England. This includes over 900 FTE consultant neurologists. In 2023, the fill rate for recruitment into the specialty of neurology in England was 94%.
The NHS workforce has been overworked for years, leading to staff becoming burnt out and demoralised. We must be honest about the challenges we are facing. The NHS is broken but not beaten and together we will turn it around.
We have launched a 10-Year Health Plan to reform the NHS. The plan will set out a bold agenda to deliver on the three big shifts needed to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention.
A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.
Asked by: Sarah Green (Liberal Democrat - Chesham and Amersham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data his Department currently holds on waiting lists for treatment for Parkinson's Disease in England.
Answered by Andrew Gwynne
The Department does not hold data specifically on the number of people waiting for treatment for Parkinson’s disease in England. The Department does hold data on waiting times for neurology, but not broken down by specific conditions. The latest data for referral to treatment waiting times in England, from September 2024, shows there were over 234,000 patients waiting for a neurology appointment, and that 54% of patients were seen by a neurologist within 18 weeks.
There are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme (NTP).
The GIRFT National Specialty Report made recommendations designed to improve services nationally, and to support the National Health Service to deliver care more equitably across the country. The report highlighted differences in how services are delivered, and provided the opportunity to share successful initiatives between trusts to improve patient services nationally. In addition, the NTP has developed a model of integrated care for neurology services to support integrated care boards to deliver the right service, at the right time for all neurology patients, including providing care closer to home.
Once diagnosed, and with a management strategy in place, the majority of people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 neurology centres across England. Within specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support according to their needs.
No specific assessment has been made of the number of specialist Parkinson’s nurses required to meet the current need of patients in England. While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the numbers working in the wider speciality of neurology. As of July 2024, there were over 1,800 full-time equivalent (FTE) doctors working in the specialty of neurology in NHS trusts and other organisations in England. This includes over 900 FTE consultant neurologists. In 2023, the fill rate for recruitment into the specialty of neurology in England was 94%.
The NHS workforce has been overworked for years, leading to staff becoming burnt out and demoralised. We must be honest about the challenges we are facing. The NHS is broken but not beaten and together we will turn it around.
We have launched a 10-Year Health Plan to reform the NHS. The plan will set out a bold agenda to deliver on the three big shifts needed to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention.
A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.
Asked by: Dan Norris (Independent - North East Somerset and Hanham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce the waiting list for people seeking treatment to relieve the symptoms of Parkinson's disease.
Answered by Andrew Gwynne
We recognise that patients have been let down whilst they wait for the care they need, including within neurology services. The NHS Constitution sets out that 92% of patients should wait no longer than 18 weeks from referral to treatment. We will deliver an extra 40,000 operations, scans, and appointments per week, as a first step in our commitment to ensuring patients can expect to be treated within 18 weeks.
At the national level, there are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit. These initiatives aim to reduce variation and deliver care more equitably across the country.
The National Institute for Health and Care Excellence (NICE) guidance, Parkinson’s disease: Diagnosis and management in primary and secondary care, updated in 2017, sets out best practice for clinicians in the identification and treatment of Parkinson’s, in line with the latest available evidence. The guidance states that if Parkinson's is suspected, people should be referred quickly to a specialist with expertise in the differential diagnosis of this condition.
We expect integrated care boards (ICBs) and National Health Service trusts to have due regard to relevant NICE guidelines. It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines.
Once diagnosed, and with a management strategy in place, most people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 specialised neurological treatment centres across England. Within specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support, according to their needs.
Asked by: Sammy Wilson (Democratic Unionist Party - East Antrim)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what steps she is taking to ensure that people with Parkinson's who receive the health element of Universal Credit do not have to prove that they continue to live with a degenerative condition after six months in order to keep the health element of Universal Credit.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
The Work Capability Assessment (WCA) determines entitlement to the extra health-related amount of Universal Credit. It is not based on a person’s condition, but on how it affects their ability to function. It recognises that conditions can vary in their severity and therefore people with the same condition can have different WCA outcomes.
WCA reassessments are prioritised for customers on the health element of UC who report a change in their health condition. Routine department-led reassessments are scheduled according to expected prognosis length for recovery and subject to available assessment capacity.
The healthcare professional who performs the WCA, will advise a DWP decision maker on when an individual should be re-assessed. This advice is based on when the individual’s condition is expected to have improved to the point were looking for work or preparing for work may become a realistic option. For those with Limited Capability for Work, re-referral dates can be 6, 12, 18 or 24 months. For individuals with more serious or complex conditions, who have Limited Capability for Work and Work-related activity (LCWRA), a 3-year re-referral date can be chosen.
Individuals, who have LCWRA, with the most severe and lifelong health conditions or disabilities, whose level of function means that they will always have LCWRA and are unlikely ever to be able to move into work, are not routinely reassessed.